Case number 2023-2220
Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 11, 2025 | 16 | Notice from the U.S. Supreme Court regarding application for an extension of time within which to file a petition for a writ of certiorari. [1098310] [23-2218, 23-2220, 23-2221] [MVH] [Entered: 06/24/2025 04:50 PM] (3) |
| Apr 1, 2025 | 15 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [1079432] [23-2218, 23-2220, 23-2221] [MVH] [Entered: 04/01/2025 09:28 AM] (2) |
| Jan 10, 2025 | 13 | OPINION filed for the court by Lourie, Circuit Judge; Prost, Circuit Judge and Reyna, Circuit Judge. Precedential Opinion. Service as of this date by the Clerk of Court. [1059732] [23-2218, 23-2220, 23-2221] [MVH] [Entered: 01/10/2025 10:40 AM] (18) |
| Jan 10, 2025 | 14 | JUDGMENT. AFFIRMED IN PART, REVERSED IN PART. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellee(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. Service as of this date by the Clerk of Court. [1059743] [23-2218, 23-2220, 23-2221] [MVH] [Entered: 01/10/2025 10:49 AM] (2) |
| Aug 6, 2024 | 12 | ORDER The revised official caption in Appeal No. 2023-2218 and 2023-2221 is reflected in this order. The stay in Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221 is lifted. The Clerk of Court shall transmit a copy of this order to the merits panel assigned to Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221. Service as of this date by the Clerk of Court. [1023023] [23-2218, 23-2219, 23-2220, 23-2221] [LMS] [Entered: 08/06/2024 10:04 AM] (3) |
| Jul 30, 2024 | 11 | ORDER filed granting the motion [1014096-2] to the limited extent explained in the order. This court retains jurisdiction over Appeal Nos. 2023-2218 and 2023-2221. Proceedings in these consolidated cases are stayed. Novartis and Hetero shall inform this court within three days after the district court's resolution of their motion whether Hetero continues to participate in Appeal Nos. 2023-2218 and 2023-2221. Service as of this date by the Clerk of Court. [1021410] [23-2218, 23-2219, 23-2220, 23-2221] [LMS] [Entered: 07/30/2024 12:33 PM] (3) |
| Mar 6, 2024 | 10 | ORDER deconsolidating Appeal No. 2023-2260 from Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221, and dismissing Appeal No. 2023-2260.; Each side shall bear its own costs regarding Appeal No. 2023-2260. The stay in Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221 is lifted. The Clerk of Court shall transmit a copy of this order to the merits panel assigned to Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221.; issuing mandate as to Appeal No. 2023-2260 only. Service as of this date by the Clerk of Court. [988615] [23-2218, 23-2219, 23-2220, 23-2221, 23-2260] [LMS] [Entered: 03/06/2024 09:45 AM] (3) |
| Feb 22, 2024 | 9 | ORDER filed granting the motion [981228-2] to the limited extent explained in the order.; This court retains jurisdiction over Appeal No. 2023-2260. Proceedings in these consolidated cases are stayed. Novartis and Mylan shall inform this court within three days after the district court's resolution of their motion whether Appeal No. 2023-2260 is to be dismissed. Service as of this date by the Clerk of Court. [985658] [23-2218, 23-2219, 23-2220, 23-2221, 23-2260] [LMS] [Entered: 02/22/2024 12:15 PM] (4) |
| Oct 12, 2023 | 8 | Note to File: The following cases are consolidated: 23-2218 (Lead) with 23-2219, 23-2220, 23-2221, 23-2260 (Member Cases). The parties must file all documents in the lead appeal only. [956044] [23-2218, 23-2219, 23-2220, 23-2221, 23-2260] [MMA] [Entered: 10/12/2023 04:57 PM] (0) |
| Aug 24, 2023 | 7 | ORDER granting the motions [943720-2] [943725-2] to the extent that the appeals are consolidated, and thus one set of briefs should be filed for the five appeals. The revised official caption is reflected above. Appellant's opening brief is due no later than October 10, 2023. Absent objection within seven days from the date of entry of this order, the court will revise the official caption to reflect Alembic's non-participation in these appeals. Service as of this date by the Clerk of Court. [945715] [23-2218, 23-2219, 23-2220, 23-2221, 23-2260] [LMS] [Entered: 08/24/2023 03:12 PM] (3) |
| Aug 14, 2023 | 3 | Entry of Appearance for Nicholas N. Kallas; Christina Schwarz as counsel for Appellant Novartis Pharmaceuticals Corporation. Service: 08/14/2023 by email. [942936] [23-2220] [Deanne Maynard] [Entered: 08/14/2023 06:15 PM] (2) |
| Aug 14, 2023 | 4 | Certificate of Interest for Appellant Novartis Pharmaceuticals Corporation. Service: 08/14/2023 by email. [942938] [23-2220] [Deanne Maynard] [Entered: 08/14/2023 06:18 PM] (2) |
| Aug 14, 2023 | 5 | Docketing Statement for the Appellant Novartis Pharmaceuticals Corporation. Service: 08/14/2023 by email. [942939] [23-2220] [Deanne Maynard] [Entered: 08/14/2023 06:20 PM] (3) |
| Aug 14, 2023 | 6 | Notice of Related Case Information for Appellant Novartis Pharmaceuticals Corporation. Service: 08/14/2023 by email. [942941] [23-2220] [Deanne Maynard] [Entered: 08/14/2023 06:23 PM] (4) |
| Aug 2, 2023 | 2 | Entry of Appearance for Deanne E. Maynard; Seth W. Lloyd as counsel for Appellant Novartis Pharmaceuticals Corporation. Service: 08/02/2023 by email. [940092] [23-2220] [Deanne Maynard] [Entered: 08/02/2023 11:57 AM] (1) |
| Jul 31, 2023 | 1 | Appeal docketed. Received: 07/25/2023. [939668]Entry of Appearance due 08/14/2023. Certificate of Interest is due on 08/14/2023. Docketing Statement due 08/14/2023. Appellant's brief is due 09/29/2023. [MMA] [Entered: 07/31/2023 06:47 PM] (37) |
